Bafna Pharmaceuticals MD, chairman and AGM

Bafna Pharmaceuticals board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

ChairpersonRAVICHANDRAN CHITRA
Company Secretary and Compliance OfficerMOHANACHANDRAN A

6 directors2 independent2 executive2 non-executive

SHANMUGAM HEMALATHAExecutive · joined Sep 2020 · reappointed Sep 2023 · 1 listed board · 1 committee seat
VINAYAK DINESH DENDUKURIExecutive · joined Jun 2023 · 1 listed board
AKILA CHINTALAPATI RAJUNon-executive · joined Sep 2020 · 1 listed board · 1 committee seat
UPENDAR MEKALA REDDYNon-executive · joined Jun 2023 · 1 listed board · 1 committee seat
RAVICHANDRAN CHITRA · ChairpersonIndependent · joined Nov 2020 · reappointed Nov 2025 · 67 months as independent · 2 listed boards · 2 as independent · 2 committee seats, 1 as chair
PALAMADAI KRISHNAN SUNDARESANIndependent · joined Sep 2025 · reappointed Sep 2025 · 9 months as independent · 1 listed board · 1 as independent

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

2 directors who left

NAVIN KUMAR, left 22 Jun 2026: Tenure Completion
KRISHNA YEACHURI, left 31 Mar 2025: Others

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

Board
- 29 May 20267 of 7 present3 independent · 62 days in between
- 27 Mar 20266 of 7 present3 independent · 43 days in between
- 11 Feb 20266 of 7 present2 independent
Audit Committee
Chair PALAMADAI KRISHNAN SUNDARESAN
RAVICHANDRAN CHITRA, UPENDAR MEKALA REDDY
- 29 May 20263 of 3 present2 independent · 62 days in between
- 27 Mar 20263 of 3 present2 independent · 43 days in between
- 11 Feb 20263 of 3 present2 independent
Nomination and remuneration committee
Chair PALAMADAI KRISHNAN SUNDARESAN
RAVICHANDRAN CHITRA, AKILA CHINTALAPATI RAJU
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair RAVICHANDRAN CHITRA
SHANMUGAM HEMALATHA, AKILA CHINTALAPATI RAJU
No meeting listed in the filing.
Corporate Social Responsibility Committee
Chair RAVICHANDRAN CHITRA
SHANMUGAM HEMALATHA, AKILA CHINTALAPATI RAJU
No meeting listed in the filing.

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Mar 2026.

Brahmayya & CoPeer-review certificate valid to Apr 2027

1 earlier auditor

Brahmayya And CoNamed in filings from Mar 2025 to Jun 2025

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Bafna Pharmaceuticals AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Bafna Pharmaceuticals dividend history

Annual general meeting, 11 Sep 2026

7,093 shareholders on the register on 4 Sep 2026; present: 6 promoters and 58 others; votes counted by BALU SRIDHAR / M/S A K JAIN & ASSOCIATES.The company's voting result (opens in a new tab)

Adoption of Audited Financial Statements of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditor’s thereon
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 76.76% · promoters 99.99% · institutions 0.00% · other public 11.31%
Re-appointment of Mr. Upendar Mekala Reddy (DIN: 08898174), as Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 76.76% · promoters 99.99% · institutions 0.00% · other public 11.31%
Ratification of Remuneration payable to Cost Auditors M/s. N Sivashankaran & Co., Cost Accountants (ICMAI FRN. 100662) for FY 2026-2027
Ordinary
100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 76.76% · promoters 99.99% · institutions 0.00% · other public 11.31%